RecruitingNCT07373639
A Long-term Follow-up Study in Patients Who Received BEAM-101
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beam Therapeutics Inc.
- Intervention
- Long-Term Follow-up Study of patients who received BEAM-101(drug)
- Enrollment
- 50 target
- Eligibility
- 14-37 years · All sexes
- Timeline
- 2025 – 2043
Study locations (17)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston, Atlanta, Georgia, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Henry Ford Cancer Center, Detroit, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Columbia University Irving Medical Center, New York, New York, United States
- University Hospitals Clevland Medical Center, Cleveland, Ohio, United States
- The Clevland Clinic Foundation, Cleveland, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07373639 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited
- RECRUITINGPHASE1, PHASE2NCT06930703Cannabidiol in Sickle Cell DiseaseIcahn School of Medicine at Mount Sinai